Document is current
Any future updates will be listed below
-
Authors
Chhabra, Saurabh https://orcid.org/0000-0001-9117-8696
Jerkins, James H. https://orcid.org/0000-0002-2532-0604
Monahan, Kathleen
Szabo, Aniko https://orcid.org/0000-0002-8129-0614
Shah, Nirav N. https://orcid.org/0000-0002-4336-1071
Abedin, Sameem
Runaas, Lyndsey
Fenske, Timothy S.
Pasquini, Marcelo C.
Shaw, Bronwen E. https://orcid.org/0000-0003-3317-1896
Drobyski, William R. https://orcid.org/0000-0001-7121-6499
Saber, Wael
D’Souza, Anita https://orcid.org/0000-0002-1092-5643
Dhakal, Binod
Mohan, Meera https://orcid.org/0000-0002-6913-6526
Longo, Walter
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
- License Information
-
More Information
Article History
Received: 30 August 2023
Revised: 24 November 2023
Accepted: 4 December 2023
First Online: 4 January 2024
Competing interests
: SC: Honorarium from Janssen, Sanofi, GSK, and institutional research funding from Janssen, Takda, C4 Therapeutics, Abbvie. JHJ: Honorarium from Omeros. SA: Research Funding from Incyte, AltruBio, Actinium Pharmaceutical; Consultancy/Honoraria from AbbVie, Daichii Sankyo, Servier. NNS: Participation on advisory boards and/or consultancy for Kite Pharma, BMS-Juno, Miltenyi Biotec, Lilly Oncology, Epizyme, Incyte, Novartis, Seattle Genetics, Abbvie, and Gallapagos; Research funding, travel support, and honoraria from Lilly Oncology and Miltenyi Biotec; Scientific advisory board for Tundra Therapeutics. TSF: Consultancy, Speakers Bureau: Beigene, Kite (Gilead), Servier Pharmaceuticals, MorphoSys, TG Therapeutics, SeaGen, Adaptive Biotechnologies, Astrazeneca, Pharmacyclics (AbbVie), Sanofi. MCP: Research Funding: Novartis, Bristol Myers Squibb, Kite, a Gilead Company, Janssen; Consultancy: Bristol Myers Squibb; Honoraria: Kite, a Gilead Company, Kite Brazil. BES: Institutional payments from Mallinkrodt, Orcabio. AD: Membership on an entity’s Board of Directors or advisory committees: Imbrium, Pfizer; Consultancy: Bristol Myers Squibb; Janssen, Prothena; Research Funding: Abbvie, Sanofi, Takeda, TeneoBio, Caelum, Prothena. MM: Honoraria: MashupMD, Blood Cancer Today, MJH life sciences, Bristol-Myers Squibb Company; Consultancy: Sanofi S.A; Research Funding: Sanofi. S.A, Amgen Inc, Institutional KL2 Award, Celgene Corporation, Ionis Pharmaceuticals, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Novartis. MH: Research Support/Funding: ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, Genmab. Speaker’s Bureau: Sanofi Genzyme., ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. All other authors report no relevant conflicts of interest.
